X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AUROBINDO PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AUROBINDO PHARMA GLENMARK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 20.0 19.4 103.0% View Chart
P/BV x 3.5 3.6 96.2% View Chart
Dividend Yield % 0.3 0.3 87.3%  

Financials

 GLENMARK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
GLENMARK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs930809 115.0%   
Low Rs517504 102.7%   
Sales per share (Unadj.) Rs322.6281.1 114.8%  
Earnings per share (Unadj.) Rs28.541.4 68.9%  
Cash flow per share (Unadj.) Rs39.250.9 77.0%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.30.4 72.6%  
Book value per share (Unadj.) Rs183.0199.4 91.8%  
Shares outstanding (eoy) m282.17585.88 48.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.3 96.0%   
Avg P/E ratio x25.415.9 160.0%  
P/CF ratio (eoy) x18.512.9 143.1%  
Price / Book Value ratio x4.03.3 120.1%  
Dividend payout %7.06.0 116.1%   
Avg Mkt Cap Rs m204,206384,630 53.1%   
No. of employees `00013.717.3 79.1%   
Total wages/salary Rs m18,71821,308 87.8%   
Avg. sales/employee Rs Th6,636.89,500.7 69.9%   
Avg. wages/employee Rs Th1,364.71,229.4 111.0%   
Avg. net profit/employee Rs Th586.11,397.9 41.9%   
INCOME DATA
Net Sales Rs m91,031164,666 55.3%  
Other income Rs m9141,020 89.6%   
Total revenues Rs m91,945165,686 55.5%   
Gross profit Rs m16,15437,718 42.8%  
Depreciation Rs m3,0195,580 54.1%   
Interest Rs m2,856777 367.4%   
Profit before tax Rs m11,19332,380 34.6%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1558,183 38.6%   
Profit after tax Rs m8,03924,229 33.2%  
Gross profit margin %17.722.9 77.5%  
Effective tax rate %28.225.3 111.5%   
Net profit margin %8.814.7 60.0%  
BALANCE SHEET DATA
Current assets Rs m69,887121,878 57.3%   
Current liabilities Rs m32,87986,806 37.9%   
Net working cap to sales %40.721.3 190.9%  
Current ratio x2.11.4 151.4%  
Inventory Days Days81130 62.7%  
Debtors Days Days9368 136.8%  
Net fixed assets Rs m28,89281,037 35.7%   
Share capital Rs m282586 48.2%   
"Free" reserves Rs m51,353116,218 44.2%   
Net worth Rs m51,635116,804 44.2%   
Long term debt Rs m41,4184,512 917.9%   
Total assets Rs m125,954211,052 59.7%  
Interest coverage x4.942.7 11.5%   
Debt to equity ratio x0.80 2,076.5%  
Sales to assets ratio x0.70.8 92.6%   
Return on assets %8.611.8 73.0%  
Return on equity %15.620.7 75.1%  
Return on capital %15.127.4 55.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31780,727 45.0%   
Fx outflow Rs m9,72034,700 28.0%   
Net fx Rs m26,59846,027 57.8%   
CASH FLOW
From Operations Rs m16,48119,548 84.3%  
From Investments Rs m-10,133-19,570 51.8%  
From Financial Activity Rs m-4,6858,642 -54.2%  
Net Cashflow Rs m1,7708,922 19.8%  

Share Holding

Indian Promoters % 48.3 54.1 89.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.0 86.8%  
FIIs % 34.4 27.7 124.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.2 102.9%  
Shareholders   56,727 69,601 81.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  ABBOTT INDIA  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS